No Data
How Is The Market Feeling About Quest Diagnostics?
Should You Hold Quest Diagnostics Stock in Your Portfolio Now?
Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $177
Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management
Mizuho Adjusts Price Target on Quest Diagnostics to $177 From $174, Keeps Outperform Rating
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services